Salbutamol dry-powder inhalation - Teva Pharmaceutical Industries

Drug Profile

Salbutamol dry-powder inhalation - Teva Pharmaceutical Industries

Alternative Names: Airmax Salamol; Albuterol DPI - Teva; Albuterol dry-powder inhalation - Teva; Albuterol MDPI; Albuterol Spiromax; Albuterol sulfate - Teva; ProAir RespiClick; Salbutamol DPI - Teva

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator IVAX Corporation
  • Developer IVAX Corporation; Teva Pharmaceutical Industries
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Tocolytics
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Exercise-induced asthma

Most Recent Events

  • 25 Nov 2016 Teva plans a phase III trial for Asthma in USA (NCT02969408)
  • 30 Apr 2016 Launched for Asthma (In children) in USA (Inhalation)
  • 30 Apr 2016 Launched for Exercise-induced asthma (In children) in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top